The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 18 unusual trades. Delving into the details, we found 33 ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 ...

Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a receptor implicated in obesity and associated co-morbidities, has been revealed as the winner of Pioneer ...

Danish pharma group Novo Nordisk has revealed it is in exclusive ... the company’s head of devices and delivery solutions. “We have enjoyed a fruitful collaboration with Biocorp over the ...

(Reuters) -Novo Nordisk's blockbuster diabetes drug Ozempic ... the process and are among the most expensive for the Medicare health program for people aged 65 and older or with disabilities.

No Plan to Prop up Global Health, Novo Nordisk Foundation Says, as Trump Freezes US Aid By Jennifer Rigby LONDON (Reuters) - The Novo Nordisk Foundation does not plan to step in to prop up a ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital ...

Medicare’s next drug price negotiations will treat Novo Nordisk’s semaglutide as a ... widely covered within Medicare for diabetes, the health insurance program is not currently permitted ...